Loading...
•
Jun 30, 2025
Ironwood Pharmaceuticals Q2 2025 Earnings Report
Ironwood Pharmaceuticals delivered mixed second quarter 2025 results with lower total revenue but stronger LINZESS net sales and improved commercial margin.
Key Takeaways
In Q2 2025, Ironwood reported total revenue of 85239000, GAAP net income of 23599000 with diluted EPS of 0.14, non-GAAP net income of 23623000, and strong LINZESS U.S. net sales of 248000000 driven by 10% prescription demand growth and a 69% commercial margin. :contentReference[oaicite:0]{index=0}
Total revenue declined to 85239000 in Q2 2025 compared to the prior year. :contentReference[oaicite:1]{index=1}
GAAP net income was 23599000 with diluted EPS of 0.14. :contentReference[oaicite:2]{index=2}
LINZESS U.S. net sales increased 17% year-over-year to 248000000. :contentReference[oaicite:3]{index=3}
LINZESS prescription demand grew 10% to 58 million capsules and commercial margin expanded to 69%. :contentReference[oaicite:4]{index=4}
Revenue by Segment
Forward Guidance
Ironwood maintained full year 2025 guidance with expected U.S. LINZESS net sales of $800M–$850M, total revenue of $260M–$290M, and adjusted EBITDA greater than $105M. :contentReference[oaicite:7]{index=7}
Positive Outlook
- Maintained full year 2025 LINZESS U.S. net sales guidance of $800M–$850M. :contentReference[oaicite:8]{index=8}
- Total revenue guidance reaffirmed at $260M–$290M. :contentReference[oaicite:9]{index=9}
- Adjusted EBITDA expected above $105M. :contentReference[oaicite:10]{index=10}
- LINZESS demand growth remains strong. :contentReference[oaicite:11]{index=11}
- Improved commercial margin supports profitability. :contentReference[oaicite:12]{index=12}
Challenges Ahead
- Total revenue declined compared to Q2 2024. :contentReference[oaicite:13]{index=13}
- Collaboration revenue decreased year-over-year. :contentReference[oaicite:14]{index=14}
- Macroeconomic and pricing headwinds remain. :contentReference[oaicite:15]{index=15}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...